These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22580061)

  • 1. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the blood brain barrier in neurodegenerative disorders and their treatment.
    Palmer AM
    J Alzheimers Dis; 2011; 24(4):643-56. PubMed ID: 21460432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
    Amigoni F; Legnaghi E; Pevarello P
    Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of pharmacogenetics in treating central nervous system disorders.
    Patnaik M; Renda MJ; Athanasiou MC; Reed CR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the vasopressin system for the treatment of CNS diseases.
    Ryckmans T
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Chinese medicines on cAMP/PKA signaling in central nervous system dysfunction.
    Li L; Fan X; Zhang XT; Yue SQ; Sun ZY; Zhu JQ; Zhang JH; Gao XM; Zhang H
    Brain Res Bull; 2017 Jun; 132():109-117. PubMed ID: 28438669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult neurogenesis pharmacology in neurological diseases and disorders.
    Taupin P
    Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
    van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
    Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 16. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.
    Gribkoff VK; Kaczmarek LK
    Neuropharmacology; 2017 Jul; 120():11-19. PubMed ID: 26979921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.
    Choi DW; Armitage R; Brady LS; Coetzee T; Fisher W; Hyman S; Pande A; Paul S; Potter W; Roin B; Sherer T
    Neuron; 2014 Nov; 84(3):554-63. PubMed ID: 25442934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence.
    Goetghebeur PJ; Swartz JE
    J Psychopharmacol; 2016 Jul; 30(7):586-94. PubMed ID: 27147593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models of CNS disorders.
    McGonigle P
    Biochem Pharmacol; 2014 Jan; 87(1):140-9. PubMed ID: 23811310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.